Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity

BACKGROUND Lebrikizumab is a monoclonal antibody that binds with high affinity and slow dissociation rate to IL-13,thereby blocking the downstream effects ofIL-13 with high potency1 Lebrikizumab has demonstrated clinical benefit in patients with moderate-to-severe AD in the randomized, placebo-controlled, Phase 3 ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) trials2,3OBJECTIVE To assess efficacy of lebrikizumab in the ADvocate1 and ADvocate2 trials within subgroups of patients with moderate (IGA=3) vs.